Clinical Trial Update: Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) [Phase 3]

View source ↗

Summary

Phase 3 MK-0524A-108 trial evaluating a niacin/laropiprant tablet in South and Southeast Asians with low HDL cholesterol at risk for cardiovascular disease was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• MK-0524A (niacin/laropiprant) tablet (niacin/laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2014-03-14